Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors
Zilovertamab vedotin had minimal antitumor activity and manageable safety in participants with previously treated metastatic solid tumors of various histologic subtypes. The results suggest that further development of zilovertamab vedotin in these solid tumors is not warranted.
Authors
- Luis E. Raez (ORCID: https://orcid.org/0000-0003-2669-5771)
- Fengting Yan (ORCID: https://orcid.org/0000-0002-0234-4937)
- Martin Gutierrez (ORCID: https://orcid.org/0000-0003-3156-3159)
- Enrique Sanz‐García (ORCID: https://orcid.org/0000-0002-3119-3832)
- Douglas A. Levine (ORCID: https://orcid.org/0000-0003-1038-8232)
- Komal L. Jhaveri (ORCID: https://orcid.org/0000-0003-0472-1254)
- Diego R. Villa (ORCID: https://orcid.org/0000-0002-4625-3009)
- John Sarantopoulos
- Funda Meric‐Bernstam (ORCID: https://orcid.org/0000-0001-6816-6072)
- Mark A. Socinski (ORCID: https://orcid.org/0000-0003-2915-9325)
- Manash S. Chatterjee
- Quincy S. Chu (ORCID: https://orcid.org/0000-0003-4814-3126)
- Maxime Chénard-Poirier (ORCID: https://orcid.org/0000-0001-5800-0124)
- Jun Zhang (ORCID: https://orcid.org/0000-0001-7886-6187)
- Qi Liu (ORCID: https://orcid.org/0000-0001-5326-3419)
- Hong Ren
- Jennifer Friedmann
Institutions
- Ontario Institute for Cancer Research (CA)
- BC Cancer Agency (CA)
- Hackensack University Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Miami (US)
- University of Alberta (CA)
- The University of Texas at San Antonio Health Science Center (US)
- Cornell University (US)
- Jewish General Hospital (CA)
- Spinal Cord Injury BC (CA)
- Princess Margaret Cancer Centre (CA)
- Kettering University (US)
- Florida Hospital Cancer Institute (US)
- Swedish Medical Center (US)
- The University of Kansas Cancer Center (US)
- Merck Institute for Science Education (US)
- University of Kansas Medical Center (US)
- Cancer Institute of Florida (US)
- Université Laval (CA)
- Florida Atlantic University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-08-05
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0019
- Citations
- 2
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- AstraZeneca
- Gilead Sciences
- Celgene
- Memorial Sloan-Kettering Cancer Center
- BeiGene
- Incyte
- Merck Canada